{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T22:13:51Z","timestamp":1770502431474,"version":"3.49.0"},"reference-count":12,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2001,5,1]],"date-time":"2001-05-01T00:00:00Z","timestamp":988675200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2001,5,1]],"date-time":"2001-05-01T00:00:00Z","timestamp":988675200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2001,5]]},"DOI":"10.1136\/ard.60.5.514","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T10:45:32Z","timestamp":1027766732000},"page":"514-517","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Treatment with cyclosporin switching to hydroxychloroquine in patients with rheumatoid arthritis"],"prefix":"10.1016","volume":"60","author":[{"given":"W-U","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y-I","family":"Seo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S-H","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W-K","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S-K","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S-I","family":"Paek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C-S","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H-H","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H-Y","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ard.60.5.514_bib1","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJM199605163342002","article-title":"Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications.","volume":"334","author":"O'Dell","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.60.5.514_bib2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1056\/NEJM199507203330301","article-title":"Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis.","volume":"333","author":"Tugwell","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.60.5.514_bib3","doi-asserted-by":"crossref","first-page":"863","DOI":"10.7326\/0003-4819-109-11-863","article-title":"Cyclosporin A in severe, treatment-refractory rheumatoid arthritis. A randomized study.","volume":"109","author":"Yocum","year":"1988","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard.60.5.514_bib4","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(90)92630-Z","article-title":"Low-dose cyclosporine versus placebo in patients with rheumatoid arthritis.","volume":"335","author":"Tugwell","year":"1990","journal-title":"Lancet"},{"key":"10.1136\/ard.60.5.514_bib5","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/art.1780370506","article-title":"Randomized, double-blind, 24-week controlled study of low-dose cyclosporine versus chloroquine for early rheumatoid arthritis.","volume":"37","author":"Landewe","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.60.5.514_bib6","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/art.1780331001","article-title":"The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses.","volume":"33","author":"Felson","year":"1990","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.60.5.514_bib7","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/art.1780360303","article-title":"The relative toxicity of disease-modifying antirheumatic drugs.","volume":"36","author":"Fries","year":"1993","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.60.5.514_bib8","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.60.5.514_bib9","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/rheumatology\/36.7.808","article-title":"The use of cyclosporin A microemulsion in rheumatoid arthritis: conclusions of an international review.","volume":"36","author":"Panayi","year":"1997","journal-title":"Br J Rheumatol"},{"key":"10.1136\/ard.60.5.514_bib10","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/art.1780360601","article-title":"The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials.","volume":"36","author":"Felson","year":"1993","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.60.5.514_bib11","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis.","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.60.5.514_bib12","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/art.1780380305","article-title":"The total costs of drug therapy for rheumatoid arthritis. A model based on costs of drug, monitoring, and toxicity.","volume":"38","author":"Prashker","year":"1995","journal-title":"Arthritis Rheum"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724442672?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724442672?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.60.5.514","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T08:01:50Z","timestamp":1737360110000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724442672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,5]]},"references-count":12,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2001,5]]}},"alternative-id":["S0003496724442672"],"URL":"https:\/\/doi.org\/10.1136\/ard.60.5.514","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2001,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment with cyclosporin switching to hydroxychloroquine in patients with rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.60.5.514","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2001 Annals of the Rheumatic Diseases. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}